Company Overview and News
Wall Street expects a year-over-year increase in earnings on higher revenues when NextEra Energy Partners (NEP - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Enphase Energy, Inc. (ENPH - Free Report) recently announced that the leading solar contractor Solar Solution will use IQ™ solar microinverter produced by Enphase Energy in its 72-cell solar modules to provide clean solar energy to commercial, non-profit and residential customers in Washington, DC. Since 2010, Solar Solution has deployed nearly 75,000 microinverters supplied by Enphase. Washington, DC-based Solar Solution believes that the company’s IQ Micros are best suited to support 72-cell modules, as the IQ Micros provide high-power output, great reliability and reduced system outage risk, along with 25 years warranty.
ENPH NEP CSIQ
Investors interested in Alternative Energy - Other stocks are likely familiar with NextEra Energy Partners (NEP - Free Report) and Evergy Inc (EVRG - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
2018-10-04 zacks - 1
Technological advancements in recent times have brought down the cost of generating electricity from alternative energy sources and storing the same. In this backdrop, the outlook for the U.S. alternative energy stocks remains favorable as utilities and corporations are increasingly shifting to renewables. However, policy uncertainties in the nation under Trump’s administration have been an overhang on the stocks’ prospects in the near term.
GEVO DM STOHF NEP CVA STO
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
COBZ DB ABBV NEP VMW BOKF ABBV
Estimates for NextEra Energy Partners (NEP - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 73.1% and 5.7% north to $2.96 and $2.22, respectively. Units of the partnership have rallied nearly 18.7% over the past six months compared with its industry’s rally of 10.3%. NextEra Energy Partners is a growth-oriented limited partnership formed by NextEra Energy, Inc.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Schlumberger (SLB) and Biogen (BIIB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP STZ.B TXN NEP PBOWP PBOWN BIIB ICE WFC SLB UNP WLL PBI STZ PBI-B ITW SLB
Dominion Energy Inc. (D - Free Report) recently offered a proposal to acquire all outstanding units of Dominion Energy Midstream Partners (DM - Free Report) , which are not owned by the company, at 8.2% premium to the 30-day volume-weighted average unit price. The offer is made to acquire all outstanding common units in exchange for Dominion Energy common shares. Per the offer, each unit will receive 0.
Investors interested in stocks from the Alternative Energy - Other sector have probably already heard of NextEra Energy Partners (NEP - Free Report) and Evergy Inc (EVRG - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
2018-09-14 seekingalpha - 2
WallStars show positive broker target price upsides. Ten top "safer" high yield dividend Utilities WallStars showed 0.84-78% net gains as of 9/11/18 broker targets plus dividends.
JE PEGI UGI HUNGF NEP TGS BKH SBS JE CZZ PEG HNP BKHU BIP 0902 BEP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NEP / NextEra Energy Partners LP on message board site Silicon Investor.
as of ET